Tysabri and PML: What Does the Monitoring Evidence Show?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is on Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is crucial. This page summarizes the current evidence on PML monitoring, drawing from decades of pharmacovigilance research that has shaped how we track and manage this rare but serious condition. Here, we break down the essential facts on symptoms, diagnosis, and what the latest guidelines recommend.

Find Out If You Qualify for Compensation →

Medical Background and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Washington who have developed PML after Tysabri exposure, understanding the medical evidence and legal considerations—including the statute of limitations for filing a claim—is essential. PML is an infection of the brain's white matter that typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning stating that Tysabri increases the risk of PML, and that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML, withholding the drug immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against the expected benefit when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathways Linking Tysabri to PML

Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This action reduces inflammation in the central nervous system but also impairs immune surveillance against the JC virus. In immunocompromised patients, the virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The FDA label notes that PML typically occurs only in patients who are immunocompromised, and that Tysabri's mechanism of action increases this vulnerability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

PML presents with subacute neurological deficits such as progressive weakness, visual disturbances, cognitive decline, and ataxia. Diagnosis is confirmed by brain MRI showing multifocal white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. The FDA label emphasizes that Tysabri should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early recognition is critical, as outcomes are often poor despite intervention.

Adequacy of Warnings and Legal Implications

The FDA has mandated a boxed warning and a restricted distribution program called the TOUCH Prescribing Program to mitigate PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether these warnings were sufficiently communicated to patients and prescribers in Washington, particularly regarding the specific risk factors and the need for vigilant monitoring. The adequacy of warnings is a central issue in potential legal claims.

Settlement-Related Considerations for Affected Patients in Washington

For patients in Washington who have developed PML after Tysabri use, settlement considerations depend on several factors. The statute of limitations for personal injury claims in Washington is generally three years from the date the injury was discovered or should have been discovered with reasonable diligence. Given that PML symptoms may develop gradually, the timeline between exposure and documented harm is critical. The FDA label notes that PML can occur after varying durations of treatment, with risk increasing beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients should document the date of first Tysabri infusion, the onset of neurological symptoms, and the date of PML diagnosis. Legal counsel can help determine whether the claim falls within the statutory window. Settlement amounts may reflect medical expenses, lost income, pain and suffering, and the severity of disability. The FDA label states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), which can influence compensation. Prior use of immunosuppressants, as noted in the label, may also affect risk assessment and liability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Timeline Between Exposure and Documented Harm

The latency period between starting Tysabri and PML diagnosis varies. The FDA label identifies longer treatment duration, especially beyond two years, as a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have been reported after shorter exposure. For legal purposes, the clock for the statute of limitations typically starts when the patient knew or should have known that PML was caused by Tysabri. This may be the date of diagnosis or when a physician first suspects the link. Patients should retain all medical records, infusion logs, and correspondence with healthcare providers.

Conclusion

Tysabri-associated PML is a devastating condition with high morbidity and mortality. The FDA has provided clear warnings and risk mitigation strategies, but affected patients in Washington must act promptly to preserve their legal rights. Understanding the medical evidence—including risk factors, clinical presentation, and mechanistic pathways—is essential for evaluating potential claims. Consultation with a qualified attorney experienced in pharmaceutical litigation is strongly recommended to navigate the statute of limitations and settlement process.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Washington?

In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or should have been discovered with reasonable diligence. For Tysabri-associated PML, this typically starts when the patient knew or should have known that PML was caused by Tysabri, often the date of diagnosis. It is crucial to consult an attorney to determine if your claim falls within this window.

What are the risk factors for developing PML from Tysabri?

The FDA has identified three key risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against the expected benefit when initiating or continuing therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Tysabri

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.